These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 26088352

  • 1. Glycogen phosphorylase as a target for type 2 diabetes: synthetic, biochemical, structural and computational evaluation of novel N-acyl-N´-(β-D-glucopyranosyl) urea inhibitors.
    Kantsadi AL, Parmenopoulou V, Bakalov DN, Snelgrove L, Stravodimos GA, Chatzileontiadou DS, Manta S, Panagiotopoulou A, Hayes JM, Komiotis D, Leonidas DD.
    Curr Top Med Chem; 2015; 15(23):2373-89. PubMed ID: 26088352
    [Abstract] [Full Text] [Related]

  • 2. Crystallographic and computational studies on 4-phenyl-N-(beta-D-glucopyranosyl)-1H-1,2,3-triazole-1-acetamide, an inhibitor of glycogen phosphorylase: comparison with alpha-D-glucose, N-acetyl-beta-D-glucopyranosylamine and N-benzoyl-N'-beta-D-glucopyranosyl urea binding.
    Alexacou KM, Hayes JM, Tiraidis C, Zographos SE, Leonidas DD, Chrysina ED, Archontis G, Oikonomakos NG, Paul JV, Varghese B, Loganathan D.
    Proteins; 2008 May 15; 71(3):1307-23. PubMed ID: 18041758
    [Abstract] [Full Text] [Related]

  • 3. Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: recent developments.
    Somsák L, Nagya V, Hadady Z, Docsa T, Gergely P.
    Curr Pharm Des; 2003 May 15; 9(15):1177-89. PubMed ID: 12769745
    [Abstract] [Full Text] [Related]

  • 4. N-(4-Substituted-benzoyl)-N'-(β-d-glucopyranosyl)ureas as inhibitors of glycogen phosphorylase: Synthesis and evaluation by kinetic, crystallographic, and molecular modelling methods.
    Nagy V, Felföldi N, Kónya B, Praly JP, Docsa T, Gergely P, Chrysina ED, Tiraidis C, Kosmopoulou MN, Alexacou KM, Konstantakaki M, Leonidas DD, Zographos SE, Oikonomakos NG, Kozmon S, Tvaroška I, Somsák L.
    Bioorg Med Chem; 2012 Mar 01; 20(5):1801-16. PubMed ID: 22325154
    [Abstract] [Full Text] [Related]

  • 5. Design and Synthesis of 3-(β-d-Glucopyranosyl)-4-amino/4-guanidino Pyrazole Derivatives and Analysis of Their Glycogen Phosphorylase Inhibitory Potential.
    Kun S, Mathomes RT, Docsa T, Somsák L, Hayes JM.
    Molecules; 2023 Mar 28; 28(7):. PubMed ID: 37049768
    [Abstract] [Full Text] [Related]

  • 6. Synthesis of N-glucopyranosidic derivatives as potential inhibitors that bind at the catalytic site of glycogen phosphorylase.
    Gimisis T.
    Mini Rev Med Chem; 2010 Oct 28; 10(12):1127-38. PubMed ID: 20716054
    [Abstract] [Full Text] [Related]

  • 7. A multidisciplinary study of 3-(β-d-glucopyranosyl)-5-substituted-1,2,4-triazole derivatives as glycogen phosphorylase inhibitors: Computation, synthesis, crystallography and kinetics reveal new potent inhibitors.
    Kun S, Begum J, Kyriakis E, Stamati ECV, Barkas TA, Szennyes E, Bokor É, Szabó KE, Stravodimos GA, Sipos Á, Docsa T, Gergely P, Moffatt C, Patraskaki MS, Kokolaki MC, Gkerdi A, Skamnaki VT, Leonidas DD, Somsák L, Hayes JM.
    Eur J Med Chem; 2018 Mar 10; 147():266-278. PubMed ID: 29453094
    [Abstract] [Full Text] [Related]

  • 8. 3'-axial CH2 OH substitution on glucopyranose does not increase glycogen phosphorylase inhibitory potency. QM/MM-PBSA calculations suggest why.
    Manta S, Xipnitou A, Kiritsis C, Kantsadi AL, Hayes JM, Skamnaki VT, Lamprakis C, Kontou M, Zoumpoulakis P, Zographos SE, Leonidas DD, Komiotis D.
    Chem Biol Drug Des; 2012 May 10; 79(5):663-73. PubMed ID: 22296957
    [Abstract] [Full Text] [Related]

  • 9. Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.
    Thomson SA, Banker P, Bickett DM, Boucheron JA, Carter HL, Clancy DC, Cooper JP, Dickerson SH, Garrido DM, Nolte RT, Peat AJ, Sheckler LR, Sparks SM, Tavares FX, Wang L, Wang TY, Weiel JE.
    Bioorg Med Chem Lett; 2009 Feb 15; 19(4):1177-82. PubMed ID: 19138846
    [Abstract] [Full Text] [Related]

  • 10. Binding of N-acetyl-N '-beta-D-glucopyranosyl urea and N-benzoyl-N '-beta-D-glucopyranosyl urea to glycogen phosphorylase b: kinetic and crystallographic studies.
    Oikonomakos NG, Kosmopoulou M, Zographos SE, Leonidas DD, Chrysina ED, Somsák L, Nagy V, Praly JP, Docsa T, Tóth B, Gergely P.
    Eur J Biochem; 2002 Mar 15; 269(6):1684-96. PubMed ID: 11895439
    [Abstract] [Full Text] [Related]

  • 11. Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.
    Goyard D, Kónya B, Chajistamatiou AS, Chrysina ED, Leroy J, Balzarin S, Tournier M, Tousch D, Petit P, Duret C, Maurel P, Somsák L, Docsa T, Gergely P, Praly JP, Azay-Milhau J, Vidal S.
    Eur J Med Chem; 2016 Jan 27; 108():444-454. PubMed ID: 26708111
    [Abstract] [Full Text] [Related]

  • 12. Glucose analogue inhibitors of glycogen phosphorylase: the design of potential drugs for diabetes.
    Martin JL, Veluraja K, Ross K, Johnson LN, Fleet GW, Ramsden NG, Bruce I, Orchard MG, Oikonomakos NG, Papageorgiou AC.
    Biochemistry; 1991 Oct 22; 30(42):10101-16. PubMed ID: 1931942
    [Abstract] [Full Text] [Related]

  • 13. 1-(3-Deoxy-3-fluoro-beta-d-glucopyranosyl) pyrimidine derivatives as inhibitors of glycogen phosphorylase b: Kinetic, crystallographic and modelling studies.
    Tsirkone VG, Tsoukala E, Lamprakis C, Manta S, Hayes JM, Skamnaki VT, Drakou C, Zographos SE, Komiotis D, Leonidas DD.
    Bioorg Med Chem; 2010 May 15; 18(10):3413-25. PubMed ID: 20430629
    [Abstract] [Full Text] [Related]

  • 14. Glycogen phosphorylase inhibitor N-(3,5-dimethyl-Benzoyl)-N'-(β-D-glucopyranosyl)urea improves glucose tolerance under normoglycemic and diabetic conditions and rearranges hepatic metabolism.
    Nagy L, Docsa T, Szántó M, Brunyánszki A, Hegedűs C, Márton J, Kónya B, Virág L, Somsák L, Gergely P, Bai P.
    PLoS One; 2013 May 15; 8(7):e69420. PubMed ID: 23936011
    [Abstract] [Full Text] [Related]

  • 15. Sourcing the affinity of flavonoids for the glycogen phosphorylase inhibitor site via crystallography, kinetics and QM/MM-PBSA binding studies: comparison of chrysin and flavopiridol.
    Tsitsanou KE, Hayes JM, Keramioti M, Mamais M, Oikonomakos NG, Kato A, Leonidas DD, Zographos SE.
    Food Chem Toxicol; 2013 Nov 15; 61():14-27. PubMed ID: 23279842
    [Abstract] [Full Text] [Related]

  • 16. Probing the β-pocket of the active site of human liver glycogen phosphorylase with 3-(C-β-d-glucopyranosyl)-5-(4-substituted-phenyl)-1, 2, 4-triazole inhibitors.
    Kyriakis E, Solovou TGA, Kun S, Czifrák K, Szőcs B, Juhász L, Bokor É, Stravodimos GA, Kantsadi AL, Chatzileontiadou DSM, Skamnaki VT, Somsák L, Leonidas DD.
    Bioorg Chem; 2018 Apr 15; 77():485-493. PubMed ID: 29454281
    [Abstract] [Full Text] [Related]

  • 17. Synthesis, In Silico and Kinetics Evaluation of N-(β-d-glucopyranosyl)-2-arylimidazole-4(5)-carboxamides and N-(β-d-glucopyranosyl)-4(5)-arylimidazole-2-carboxamides as Glycogen Phosphorylase Inhibitors.
    Homolya L, Mathomes RT, Varga L, Docsa T, Juhász L, Hayes JM, Somsák L.
    Int J Mol Sci; 2024 Apr 23; 25(9):. PubMed ID: 38731811
    [Abstract] [Full Text] [Related]

  • 18. Identification of C-β-d-Glucopyranosyl Azole-Type Inhibitors of Glycogen Phosphorylase That Reduce Glycogenolysis in Hepatocytes: In Silico Design, Synthesis, in Vitro Kinetics, and ex Vivo Studies.
    Barr D, Szennyes E, Bokor É, Al-Oanzi ZH, Moffatt C, Kun S, Docsa T, Sipos Á, Davies MP, Mathomes RT, Snape TJ, Agius L, Somsák L, Hayes JM.
    ACS Chem Biol; 2019 Jul 19; 14(7):1460-1470. PubMed ID: 31243960
    [Abstract] [Full Text] [Related]

  • 19. The binding of β-d-glucopyranosyl-thiosemicarbazone derivatives to glycogen phosphorylase: A new class of inhibitors.
    Alexacou KM, Tenchiu Deleanu AC, Chrysina ED, Charavgi MD, Kostas ID, Zographos SE, Oikonomakos NG, Leonidas DD.
    Bioorg Med Chem; 2010 Nov 15; 18(22):7911-22. PubMed ID: 20947361
    [Abstract] [Full Text] [Related]

  • 20. Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes.
    Klabunde T, Wendt KU, Kadereit D, Brachvogel V, Burger HJ, Herling AW, Oikonomakos NG, Kosmopoulou MN, Schmoll D, Sarubbi E, von Roedern E, Schönafinger K, Defossa E.
    J Med Chem; 2005 Oct 06; 48(20):6178-93. PubMed ID: 16190745
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.